Skip to main content
Top
Published in: European Journal of Clinical Microbiology & Infectious Diseases 3/2013

01-03-2013 | Article

Role of K1 capsule antigen in cirrhotic patients with Escherichia coli spontaneous bacterial peritonitis in southern Taiwan

Authors: M. C. Wang, W. H. Lin, C. C. Tseng, A. B. Wu, C. H. Teng, J. J. Yan, J. J. Wu

Published in: European Journal of Clinical Microbiology & Infectious Diseases | Issue 3/2013

Login to get access

Abstract

Spontaneous bacterial peritonitis (SBP) is one of the most serious complications in patients with cirrhosis. This study aimed to investigate the prevalence of SBP caused by Escherichia coli isolates with or without the K1 capsule antigen in cirrhotic patients and the outcome. From January 2004 to January 2012, a total of 54 and 41 E. coli strains derived from patients with SBP and intestinal perforation (IP), respectively, were included for comparison in this study. Bacterial characteristics including phylogenetic groups, K1 capsule antigen, and 14 virulence factor genetic determinants, as well as data regarding patient characteristics, clinical manifestations, and in-hospital deaths, were collected and analyzed. The prevalence of the K1 capsule antigen gene neuA was more common in SBP isolates compared to IP isolates (28 % vs. 10 %, p = 0.0385). Phylogenetic groups B2 and group D were dominant in E. coli isolates with and without the K1 capsule antigen, respectively. The prevalence of virulence factors genes papG II, ompT, and usp was higher in E. coli K1 strains. There were 26 deaths (48 %) during hospitalization. Presence of the K1 capsule antigen in E. coli isolates was significantly associated with in-hospital death in cirrhotic patients with SBP (42 % vs. 14 %, p = 0.0331). This study demonstrates a higher prevalence of the K1 capsule antigen in E. coli SBP compared to E. coli peritonitis caused by IP. There were significant associations between the K1 capsule antigen and in-hospital mortality and bacterial virulence in cirrhotic patients with E. coli SBP.
Literature
1.
go back to reference Lata J, Stiburek O, Kopacova M (2009) Spontaneous bacterial peritonitis: a severe complication of liver cirrhosis. World J Gastroenterol 15(44):5505–5510PubMedCrossRef Lata J, Stiburek O, Kopacova M (2009) Spontaneous bacterial peritonitis: a severe complication of liver cirrhosis. World J Gastroenterol 15(44):5505–5510PubMedCrossRef
2.
go back to reference Cheong HS, Kang CI, Lee JA, Moon SY, Joung MK, Chung DR, Koh KC, Lee NY, Song JH, Peck KR (2009) Clinical significance and outcome of nosocomial acquisition of spontaneous bacterial peritonitis in patients with liver cirrhosis. Clin Infect Dis 48(9):1230–1236PubMedCrossRef Cheong HS, Kang CI, Lee JA, Moon SY, Joung MK, Chung DR, Koh KC, Lee NY, Song JH, Peck KR (2009) Clinical significance and outcome of nosocomial acquisition of spontaneous bacterial peritonitis in patients with liver cirrhosis. Clin Infect Dis 48(9):1230–1236PubMedCrossRef
3.
go back to reference Lee JM, Han KH, Ahn SH (2009) Ascites and spontaneous bacterial peritonitis: an Asian perspective. J Gastroenterol Hepatol 24(9):1494–1503PubMedCrossRef Lee JM, Han KH, Ahn SH (2009) Ascites and spontaneous bacterial peritonitis: an Asian perspective. J Gastroenterol Hepatol 24(9):1494–1503PubMedCrossRef
4.
go back to reference Căruntu FA, Benea L (2006) Spontaneous bacterial peritonitis: pathogenesis, diagnosis, treatment. J Gastrointest Liver Dis 15(1):51–56 Căruntu FA, Benea L (2006) Spontaneous bacterial peritonitis: pathogenesis, diagnosis, treatment. J Gastrointest Liver Dis 15(1):51–56
5.
go back to reference Bert F, Johnson JR, Ouattara B, Leflon-Guibout V, Johnston B, Marcon E, Valla D, Moreau R, Nicolas-Chanoine MH (2010) Genetic diversity and virulence profiles of Escherichia coli isolates causing spontaneous bacterial peritonitis and bacteremia in patients with cirrhosis. J Clin Microbiol 48:2709–2714PubMedCrossRef Bert F, Johnson JR, Ouattara B, Leflon-Guibout V, Johnston B, Marcon E, Valla D, Moreau R, Nicolas-Chanoine MH (2010) Genetic diversity and virulence profiles of Escherichia coli isolates causing spontaneous bacterial peritonitis and bacteremia in patients with cirrhosis. J Clin Microbiol 48:2709–2714PubMedCrossRef
6.
go back to reference Bert F, Panhard X, Johnson J, Lecuyer H, Moreau R, Le Grand J, Johnston B, Sinègre M, Valla D, Nicolas-Chanoine MH (2008) Genetic background of Escherichia coli isolates from patients with spontaneous bacterial peritonitis: relationship with host factors and prognosis. Clin Microbiol Infect 14(11):1034–1040PubMedCrossRef Bert F, Panhard X, Johnson J, Lecuyer H, Moreau R, Le Grand J, Johnston B, Sinègre M, Valla D, Nicolas-Chanoine MH (2008) Genetic background of Escherichia coli isolates from patients with spontaneous bacterial peritonitis: relationship with host factors and prognosis. Clin Microbiol Infect 14(11):1034–1040PubMedCrossRef
7.
go back to reference Song KH, Jeon JH, Park WB, Park SW, Kim HB, Oh MD, Lee HS, Kim NJ, Choe KW (2009) Clinical outcomes of spontaneous bacterial peritonitis due to extended-spectrum beta-lactamase-producing Escherichia coli and Klebsiella species: a retrospective matched case–control study. BMC Infect Dis 9:41PubMedCrossRef Song KH, Jeon JH, Park WB, Park SW, Kim HB, Oh MD, Lee HS, Kim NJ, Choe KW (2009) Clinical outcomes of spontaneous bacterial peritonitis due to extended-spectrum beta-lactamase-producing Escherichia coli and Klebsiella species: a retrospective matched case–control study. BMC Infect Dis 9:41PubMedCrossRef
8.
go back to reference Wilson JW, Schurr MJ, LeBlanc CL, Ramamurthy R, Buchanan KL, Nickerson CA (2002) Mechanisms of bacterial pathogenicity. Postgrad Med J 78(918):216–224PubMedCrossRef Wilson JW, Schurr MJ, LeBlanc CL, Ramamurthy R, Buchanan KL, Nickerson CA (2002) Mechanisms of bacterial pathogenicity. Postgrad Med J 78(918):216–224PubMedCrossRef
9.
go back to reference Scholl D, Adhya S, Merril C (2005) Escherichia coli K1’s capsule is a barrier to bacteriophage T7. Appl Environ Microbiol 71(8):4872–4874PubMedCrossRef Scholl D, Adhya S, Merril C (2005) Escherichia coli K1’s capsule is a barrier to bacteriophage T7. Appl Environ Microbiol 71(8):4872–4874PubMedCrossRef
10.
go back to reference Kim KS, Itabashi H, Gemski P, Sadoff J, Warren RL, Cross AS (1992) The K1 capsule is the critical determinant in the development of Escherichia coli meningitis in the rat. J Clin Invest 90(3):897–905PubMedCrossRef Kim KS, Itabashi H, Gemski P, Sadoff J, Warren RL, Cross AS (1992) The K1 capsule is the critical determinant in the development of Escherichia coli meningitis in the rat. J Clin Invest 90(3):897–905PubMedCrossRef
11.
go back to reference Johnson JR, Oswald E, O’Bryan TT, Kuskowski MA, Spanjaard L (2002) Phylogenetic distribution of virulence-associated genes among Escherichia coli isolates associated with neonatal bacterial meningitis in the Netherlands. J Infect Dis 185(6):774–784PubMedCrossRef Johnson JR, Oswald E, O’Bryan TT, Kuskowski MA, Spanjaard L (2002) Phylogenetic distribution of virulence-associated genes among Escherichia coli isolates associated with neonatal bacterial meningitis in the Netherlands. J Infect Dis 185(6):774–784PubMedCrossRef
12.
go back to reference Bonacorsi S, Houdouin V, Mariani-Kurkdjian P, Mahjoub-Messai F, Bingen E (2006) Comparative prevalence of virulence factors in Escherichia coli causing urinary tract infection in male infants with and without bacteremia. J Clin Microbiol 44(3):1156–1158PubMedCrossRef Bonacorsi S, Houdouin V, Mariani-Kurkdjian P, Mahjoub-Messai F, Bingen E (2006) Comparative prevalence of virulence factors in Escherichia coli causing urinary tract infection in male infants with and without bacteremia. J Clin Microbiol 44(3):1156–1158PubMedCrossRef
13.
go back to reference Soriano G, Coll P, Guarner C, Such J, Sánchez F, Prats G, Vilardell F (1995) Escherichia coli capsular polysaccharide and spontaneous bacterial peritonitis in cirrhosis. Hepatology 21(3):668–673PubMedCrossRef Soriano G, Coll P, Guarner C, Such J, Sánchez F, Prats G, Vilardell F (1995) Escherichia coli capsular polysaccharide and spontaneous bacterial peritonitis in cirrhosis. Hepatology 21(3):668–673PubMedCrossRef
14.
go back to reference Rimola A, García-Tsao G, Navasa M, Piddock LJ, Planas R, Bernard B, Inadomi JM (2000) Diagnosis, treatment and prophylaxis of spontaneous bacterial peritonitis: a consensus document. International Ascites Club. J Hepatol 32(1):142–153PubMedCrossRef Rimola A, García-Tsao G, Navasa M, Piddock LJ, Planas R, Bernard B, Inadomi JM (2000) Diagnosis, treatment and prophylaxis of spontaneous bacterial peritonitis: a consensus document. International Ascites Club. J Hepatol 32(1):142–153PubMedCrossRef
15.
go back to reference Durand F, Valla D (2005) Assessment of the prognosis of cirrhosis: Child–Pugh versus MELD. J Hepatol 42(Suppl 1):S100–S107PubMedCrossRef Durand F, Valla D (2005) Assessment of the prognosis of cirrhosis: Child–Pugh versus MELD. J Hepatol 42(Suppl 1):S100–S107PubMedCrossRef
16.
go back to reference Kamath PS, Wiesner RH, Malinchoc M, Kremers W, Therneau TM, Kosberg CL, D’Amico G, Dickson ER, Kim WR (2001) A model to predict survival in patients with end-stage liver disease. Hepatology 33(2):464–470PubMedCrossRef Kamath PS, Wiesner RH, Malinchoc M, Kremers W, Therneau TM, Kosberg CL, D’Amico G, Dickson ER, Kim WR (2001) A model to predict survival in patients with end-stage liver disease. Hepatology 33(2):464–470PubMedCrossRef
17.
go back to reference Clinical and Laboratory Standards Institute (2011) Performance standards for antimicrobial susceptibility testing; twenty-first informational supplement. CLSI document M100-S21. CLSI, Wayne Clinical and Laboratory Standards Institute (2011) Performance standards for antimicrobial susceptibility testing; twenty-first informational supplement. CLSI document M100-S21. CLSI, Wayne
18.
go back to reference Ferraro MJ, Gilligan PH, Saubolle MA, Weissfeld AS (1995) Bacteriology. In: Murray PR, Baron EJ, Pfaller MA, Tenover FC, Yolken RH (eds) Manual of clinical microbiology, 6th edn. ASM Press, Washington, DC, pp 246–262 Ferraro MJ, Gilligan PH, Saubolle MA, Weissfeld AS (1995) Bacteriology. In: Murray PR, Baron EJ, Pfaller MA, Tenover FC, Yolken RH (eds) Manual of clinical microbiology, 6th edn. ASM Press, Washington, DC, pp 246–262
19.
go back to reference Wang MC, Tseng CC, Wu AB, Huang JJ, Sheu BS, Wu JJ (2009) Different roles of host and bacterial factors in Escherichia coli extra-intestinal infections. Clin Microbiol Infect 15(4):372–379PubMedCrossRef Wang MC, Tseng CC, Wu AB, Huang JJ, Sheu BS, Wu JJ (2009) Different roles of host and bacterial factors in Escherichia coli extra-intestinal infections. Clin Microbiol Infect 15(4):372–379PubMedCrossRef
20.
go back to reference Tseng CC, Wu JJ, Liu HL, Sung JM, Huang JJ (2002) Roles of host and bacterial virulence factors in the development of upper urinary tract infection caused by Escherichia coli. Am J Kidney Dis 39(4):744–752PubMedCrossRef Tseng CC, Wu JJ, Liu HL, Sung JM, Huang JJ (2002) Roles of host and bacterial virulence factors in the development of upper urinary tract infection caused by Escherichia coli. Am J Kidney Dis 39(4):744–752PubMedCrossRef
21.
go back to reference Robbins JB, McCracken GH Jr, Gotschlich EC, Orskov F, Orskov I, Hanson LA (1974) Escherichia coli K1 capsular polysaccharide associated with neonatal meningitis. N Engl J Med 290(22):1216–1220PubMedCrossRef Robbins JB, McCracken GH Jr, Gotschlich EC, Orskov F, Orskov I, Hanson LA (1974) Escherichia coli K1 capsular polysaccharide associated with neonatal meningitis. N Engl J Med 290(22):1216–1220PubMedCrossRef
22.
go back to reference McCracken GH Jr, Sarff LD, Glode MP, Mize SG, Schiffer MS, Robbins JB, Gotschlich EC, Orskov I, Orskov F (1974) Relation between Escherichia coli K1 capsular polysaccharide antigen and clinical outcome in neonatal meningitis. Lancet 2(7875):246–250PubMedCrossRef McCracken GH Jr, Sarff LD, Glode MP, Mize SG, Schiffer MS, Robbins JB, Gotschlich EC, Orskov I, Orskov F (1974) Relation between Escherichia coli K1 capsular polysaccharide antigen and clinical outcome in neonatal meningitis. Lancet 2(7875):246–250PubMedCrossRef
23.
24.
go back to reference Marklund BI, Tennent JM, Garcia E, Hamers A, Båga M, Lindberg F, Gaastra W, Normark S (1992) Horizontal gene transfer of the Escherichia coli pap and prs pili operons as a mechanism for the development of tissue-specific adhesive properties. Mol Microbiol 6(16):2225–2242PubMedCrossRef Marklund BI, Tennent JM, Garcia E, Hamers A, Båga M, Lindberg F, Gaastra W, Normark S (1992) Horizontal gene transfer of the Escherichia coli pap and prs pili operons as a mechanism for the development of tissue-specific adhesive properties. Mol Microbiol 6(16):2225–2242PubMedCrossRef
25.
go back to reference Jauréguy F, Carbonnelle E, Bonacorsi S, Clec’h C, Casassus P, Bingen E, Picard B, Nassif X, Lortholary O (2007) Host and bacterial determinants of initial severity and outcome of Escherichia coli sepsis. Clin Microbiol Infect 13(9):854–862PubMedCrossRef Jauréguy F, Carbonnelle E, Bonacorsi S, Clec’h C, Casassus P, Bingen E, Picard B, Nassif X, Lortholary O (2007) Host and bacterial determinants of initial severity and outcome of Escherichia coli sepsis. Clin Microbiol Infect 13(9):854–862PubMedCrossRef
26.
go back to reference Hui CY, Guo Y, He QS, Peng L, Wu SC, Cao H, Huang SH (2010) Escherichia coli outer membrane protease OmpT confers resistance to urinary cationic peptides. Microbiol Immunol 54(8):452–459PubMedCrossRef Hui CY, Guo Y, He QS, Peng L, Wu SC, Cao H, Huang SH (2010) Escherichia coli outer membrane protease OmpT confers resistance to urinary cationic peptides. Microbiol Immunol 54(8):452–459PubMedCrossRef
27.
go back to reference Stumpe S, Schmid R, Stephens DL, Georgiou G, Bakker EP (1998) Identification of OmpT as the protease that hydrolyzes the antimicrobial peptide protamine before it enters growing cells of Escherichia coli. J Bacteriol 180(15):4002–4006PubMed Stumpe S, Schmid R, Stephens DL, Georgiou G, Bakker EP (1998) Identification of OmpT as the protease that hydrolyzes the antimicrobial peptide protamine before it enters growing cells of Escherichia coli. J Bacteriol 180(15):4002–4006PubMed
28.
go back to reference Kanamaru S, Kurazono H, Ishitoya S, Terai A, Habuchi T, Nakano M, Ogawa O, Yamamoto S (2003) Distribution and genetic association of putative uropathogenic virulence factors iroN, iha, kpsMT, ompT and usp in Escherichia coli isolated from urinary tract infections in Japan. J Urol 170(6 Pt 1):2490–2493PubMedCrossRef Kanamaru S, Kurazono H, Ishitoya S, Terai A, Habuchi T, Nakano M, Ogawa O, Yamamoto S (2003) Distribution and genetic association of putative uropathogenic virulence factors iroN, iha, kpsMT, ompT and usp in Escherichia coli isolated from urinary tract infections in Japan. J Urol 170(6 Pt 1):2490–2493PubMedCrossRef
Metadata
Title
Role of K1 capsule antigen in cirrhotic patients with Escherichia coli spontaneous bacterial peritonitis in southern Taiwan
Authors
M. C. Wang
W. H. Lin
C. C. Tseng
A. B. Wu
C. H. Teng
J. J. Yan
J. J. Wu
Publication date
01-03-2013
Publisher
Springer-Verlag
Published in
European Journal of Clinical Microbiology & Infectious Diseases / Issue 3/2013
Print ISSN: 0934-9723
Electronic ISSN: 1435-4373
DOI
https://doi.org/10.1007/s10096-012-1757-9

Other articles of this Issue 3/2013

European Journal of Clinical Microbiology & Infectious Diseases 3/2013 Go to the issue
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine